Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MARX Biotech CoROCO:7731 -3.18%10 EBITDA Margin % is 34.96% as of Dec. 2025, which is 455% above its 10-year median of 6.30. GuruFocus rates ROCO:7731 with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 665 Healthcare Providers & Services companies, MARX Biotech Co ranks better than 60% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. MARX Biotech Co's EBITDA for the
six
months ended in Dec. 2025 was NT$114.3 Mil. MARX Biotech Co's Revenue for the
six
months ended in Dec. 2025 was NT$326.9 Mil. Therefore, MARX Biotech Co's EBITDA margin for the quarter that ended in Dec. 2025 was 34.96%.
MARX Biotech Co (ROCO:7731) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MARX Biotech Co EBITDA Margin % Related Terms
MARX Biotech Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for MARX Biotech Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MARX Biotech Co EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, MARX Biotech Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MARX Biotech Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MARX Biotech Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MARX Biotech Co (ROCO:7731) has a EBITDA Margin % of 34.96% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MARX Biotech Co and its competitors. This is 455% above median its historical median of 6.30. According to the industry distribution chart, MARX Biotech Co ranks #266 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 40%.
Is MARX Biotech Co's EBITDA Margin % too high?
MARX Biotech Co's current EBITDA Margin % of 34.96% is 455% above median its 10-year median of 6.30. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. MARX Biotech Co's value of 34.96% is 241.4% above this industry median. Based on the distribution chart, MARX Biotech Co ranks #266 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MARX Biotech Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, MARX Biotech Co ranks #266 out of 665 companies for EBITDA Margin %. This puts MARX Biotech Co in the upper half of its industry. The industry median EBITDA Margin % is 10.24. MARX Biotech Co's value of 34.96% is 241.4% above this benchmark. While the company's 10-year median is 6.30 vs. the industry median of 10.24, MARX Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MARX Biotech Co's current EBITDA Margin % of 34.96% is 241.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MARX Biotech Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MARX Biotech Co's current EBITDA Margin % is 34.96%, which is 455% above median its own 10-year median of 6.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current EBITDA Margin % of 34.96%. The current EBITDA Margin % is 34.96%, which is 455% above median its 10-year median of 6.30 and 241.4% above the Healthcare Providers & Services industry median of 10.24. MARX Biotech Co's overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current EBITDA Margin % is 34.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
10GF Score
Get the complete analysis for ROCO:7731
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7731 has been successfully added to your 
